Literature DB >> 23782679

BRAF analysis on a spectrum of melanocytic neoplasms: an epidemiological study across differing UV regions.

Maya Saroufim1, Robert Habib, Sarah Karram, Cleo Youssef Massad, Suad Taraif, Asif Loya, Mohammad Adib Houreih, Salwa S Sheikh, Samir S Amr, Mohamed Satti, Christian Oberkanins, Ibrahim Khalifeh.   

Abstract

BRAF mutation has been linked to the development of melanocytic tumors in homogeneous Caucasian cohorts. The role of solar UV radiation (UVR) in BRAF mutation status is poorly understood. We studied the epidemiology of BRAF mutation across a spectrum of melanocytic neoplasms in populations with differing UVR rates. Extended testing for 9 mutation types was attempted on 600 melanocytic neoplasms including banal nevi (n = 225), dysplastic nevi (n = 113), primary (n = 172), and metastatic melanomas (n = 90). Specimens were collected from 4 countries with increasing UVR rates (in kJ/m/yr): Syria (n = 45; UVR = 93.5), Lebanon (n = 225; UVR = 110), Pakistan (n = 122; UVR = 128), and Saudi Arabia (n = 208; UVR = 139). UVR was estimated from 21-year averages from The National Center for Atmospheric Research database. The overall BRAF mutation rate was 49% (268 of 545) and differed significantly by the geographic location [34% Pakistan, 49% Lebanon, 67% Syria, and 54% Saudi Arabia; P = 0.001], neoplasm type (P < 0.001), and anatomical location (P < 0.001) but not with age (P = 0.07) and gender (P = 1.0). V600E was the predominant mutation type, found in 96.3% of the cases. Incidence of melanoma was significantly greater in BRAF-negative (39%) versus BRAF-positive (17%) groups. For BRAF-positive cases, less severe lesions were systematically more frequent (P < 0.001). Multivariate analysis indicated that BRAF mutation is predicted by neoplasm type, anatomical site, and geographic location. In our Near East cohort, BRAF mutation rates varied by geographic location but not based on UVR. BRAF-positive status was associated with less severe lesions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23782679     DOI: 10.1097/DAD.0b013e318293f355

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  5 in total

Review 1.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

Review 2.  Biologically distinct subsets of nevi.

Authors:  Tova Rogers; Maria L Marino; Patricia Raciti; Manu Jain; Klaus J Busam; Michael A Marchetti; Ashfaq A Marghoob
Journal:  G Ital Dermatol Venereol       Date:  2016-04-27       Impact factor: 2.011

Review 3.  Braf V600E mutation in melanoma: translational current scenario.

Authors:  J A Guadarrama-Orozco; A Ortega-Gómez; E B Ruiz-García; H Astudillo-de la Vega; A Meneses-García; C Lopez-Camarillo
Journal:  Clin Transl Oncol       Date:  2016-01-29       Impact factor: 3.405

4.  BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center.

Authors:  Min Ren; Jing Zhang; Yunyi Kong; Qianming Bai; Peng Qi; Ling Zhang; Qian Wang; Xiaoyan Zhou; Yong Chen; Xiaoli Zhu
Journal:  Ann Transl Med       Date:  2022-01

5.  Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma.

Authors:  Erika Ruiz-Garcia; Juan A Matus-Santos; Jorge Alberto Guadarrama-Orozco; Miguel Angel Alvarez-Avitia; Jose Luis Aguilar-Ponce; Edith Fernandez-Figueroa; Jessica Maldonado-Mendoza; Cesar Lopez-Camarillo; Laurence A Marchat; Saul Lino-Silva; Mario Cuellar-Hubbe; Jamie de la Garza-Salazar; Abelardo Meneses-García; Horacio Astudillo-de la Vega; Hector Martinez-Said
Journal:  J Glob Oncol       Date:  2017-06-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.